Claremore Compounding Center, Inc., Claremore, OK
Is Claremore Compounding Center, Inc. registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Claremore Compounding Center, Inc. hold a Oklahoma pharmacy license?
State board of pharmacy records for Oklahoma are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026; its license lookup is an interactive search.
Has Claremore Compounding Center, Inc. had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 untitled letter (Aug 21, 2020), 1 state handoff letter (Apr 28, 2021) and 1 FMD-145 letter (Apr 28, 2021) for Claremore Compounding Center, Inc. State board of pharmacy records for Oklahoma are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026; its license lookup is an interactive search. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Claremore Compounding Center, Inc.
- Location
- Claremore, OK
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Apr 28, 2021
- FDA Data Dashboard inspections
- 1 inspection: 1 VAI; 1 published Form 483
- Form 483 text on this page
- 1 Form 483, 3 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Claremore Compounding Center, Inc., a 503A facility, with 4 dated actions.
| Document | |||
|---|---|---|---|
| Apr 28, 2021 | State handoff letter | State Handoff Letter Issued 04/28/2021 | Not linked by FDA |
| Apr 28, 2021 | FMD-145 letter | FMD-145 Letter Issued 04/28/2021 | Not linked by FDA |
| Aug 21, 2020 | Untitled letter | Untitled Letter Issued 08/21/2020 | FDA copy (archived) |
| Jan 24, 2020 | Form 483 | 483 Issued 01/24/2020 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Claremore Compounding Center, Inc., Claremore, OK (FEI number 3004549371), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Jan 24, 2020 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3004549371 | 1115817 |
Form 483s FDA has published for this site
- Jan 24, 2020: Form 483 to Claremore Compounding Center, Inc., published Feb 24, 2020. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 3 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Jan 13, 2020 to Jan 24, 2020: 3 observations
- Firm on the cover
- , Claremore, OK 74017-3068
- FEI number
- 3004549371
- Establishment type on the cover
- Producer of non-sterile drug products
- FDA district office on the cover
- 4040 North Central Expressway, Suite 300 Dallas, TX 75204
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
You used a non-pharmaceutical grade component in the formulation of a drug product.
Specifically, your firm is using orange food color that is non-pharmaceutical grade to make drug products. Examples include lot #95806 of hydrocodone/dextromethorphan 10mg/10mg capsules made on 12/10/19 and lot #94010 of hydrocodone/dextromethorphan 5mg/5mg capsules made on 9/11/1 9.
Observation 2
There is no written testing program designed to assess the stability characteristics of drug products.
Specifically, your firm does not have a written stability testing program to determine Beyond Use Dates (BUD)/expiration dates placed on all your drug products. For example,
a) Lot #95371 of Dry Skin Moisturizing (OTC) 5% -1% Cream ( containing <Redacted B4> and hydrocortisone) made on 11 /20/19 was assigned a BUD of 360 days.
b) Lot #94404 of CCC Cold Max 100-5-10-2mg per 5mL suspension ( containing guaifenesin, phenylephrine HCI , chlorpheniramine Maleate and dextromethorphan hydrobromide) made on 10/1/19 was assigned a BUD of 180 days.
c) Lot #94402 of CCC Coughist PE 100-5-2mg per 5mL suspension (containing guaifenesin, phenylephrine HCI, and chlorpheniramine maleate) made on 10/1/19 was assigned a BUD of 180 days.
d) Jungle Juice Liquid (containing <Redacted B4> and lidocaine): Lot #92698 made on 7/9/1 9, lot #93496 made on 8/16719, and lot ~21-749 made on 10/17/19 were each assigned a BUD of 360 days. ...
Observation 3
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.
Specifically, your firm does not conduct routine testing for potency for all drug products produced by your firm. Examples include the following,
a) Lot #95371 of Dry Skin Moisturizing (OTC) 5% -1% Cream (containing <Redacted B4> and hydrocortisone) made on 11/20/19.
b) Lot #94404 of CCC Cold Max 100-5-10-2mg per 5mL suspension (containing guaifenesin, phenylephrine HCI , chlorpheniramine Maleate and dextromethorphan hydrobromide) made on 10/1/19.
c) Lot #94402 of CCC Coughist PE 100-5-2mg per 5mL suspension (containing guaifenesin, phenylephrine HCI , and chloq::iheniramine maleate) made on 10/1/19.
d) Jungle Juice Liquid (containing <Redacted B4> and lidocaine): Lot #92698 made on 7/9/19, lot #93496 made on 8/16/19, and lot #94749 made on 10/17/19.
l(~) ("1-)
e) Jungle Ointment (containing <Redacted B4> hydrocortisone and lidocaine): Lot #92655 made on 7/5/19 and lot #92915 made on 7/19/19.
l ...
State board of pharmacy records
State board of pharmacy records for Oklahoma are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026; its license lookup is an interactive search.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.